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tj.2012.0Abstract Objectives: The purpose of this study was to investigate the efﬁcacy and safety of 0.1%
tacrolimus powder in Oraguard-B for the treatment of patients with symptomatic oral lichen planus
(OLP).
Methods: This was a nonrandomized, nonblinded study conducted in the outpatient department.
The 20 patients with symptomatic OLP oral lichen planus who were asked to participate in the
study were provided with 20-g containers of the study medication. Patients were asked to use the
medication over the symptomatic areas three times a day until resolution of the lesion. Patients were
recalled to assess the drug response every 15 days.
Results: The duration of treatment ranged from 30 to 183 days, with a mean of 81.8 ± 44.4
days; all 20 patients reported a favourable response to the topical tacrolimus therapy. Eleven
patients had complete resolution of their lesions. In 16 of 20 patients, there was marked resolution
in symptoms as recorded by visual analogue scale. Out of 10 patients followed up for a period ofiffmail.com (S. Gupta).
Saud University.
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144 U. Malik et al.3 months, 5 had recurrence of their lesions but with less intensity, and the patients were symptom-
less. No serious side effects were associated with the study medication.
Conclusion: Topical tacrolimus 0.1% in Oraguard-B was effective and safe in treating patients
with OLP. However, there is still a need to undertake more detailed and objective clinical studies
to determine the exact beneﬁt of tacrolimus compared with conventional therapies and examine
the inﬂuence of different dose regimes and formulations and assess the incidence of recurrence.
ª 2012 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Oral lichen planus (OLP) is a chronic inﬂammatory mucocuta-
neous disorder affecting the stratiﬁed squamous epithelium,
with a prevalence of 0.02–1.2% among the various populations
(Eisen et al., 2005). Among the prevalent group, 15% of pa-
tients with predominantly OLP develop cutaneous lesions
(Eisen, 2003).
OLP most commonly affects individuals in the 5th and 6th
decade of life with a female preponderance. Intraoral presenta-
tion of lesions is divided into three forms, namely, reticular,
atrophic (erythematous), and erosive (ulcerative and bullous),
with the posterior buccal mucosa the most frequently affected
site (Eisen, 2003; DeRossi and Ciarrocca, 2005; Sugerman and
Savage, 2002). The risk of malignant transformation of OLP is
very low but cannot be overlooked (Rajentheran et al., 1999).
Aetiological factors include hepatitis C virus; psychological
stress (high levels of anxiety or depression); contact hypersen-
sitivity to dental materials, especially to amalgam; herpes
viruses (HSV1, EBV, and HHV6); HIV; HPV; and hepatitis
B virus (Pilli et al., 2002; Thornhill et al., 2003). Although
the pathogenesis of OLP is chieﬂy unknown, a large body of
evidence supports the role of immune dysregulation. Numer-
ous topical and systemic treatments for OLP have been re-
ported to be effective, including corticosteroids (both topical
and systemic), retinoids, ultraviolet phototherapy, steroid
sparing agents (hydroxychloroquine, azathioprine, mycophen-
olate mofetil), and pimecrolimus.
Although the above-mentioned drugs have shown positive
results in the treatment of OLP, resistance to treatment and
a high risk of toxicities limit their use (Al-Hashimi et al.,
2007). Tacrolimus is a newer immunosuppressant that has re-
cently been shown to be effective and safe in the treatment of
symptomatic OLP (Kaliakatsou et al., 2002). Tacrolimus is
10–100 times as potent as cyclosporine in its ability to inhibit
IL-2 mRNA synthesis, and it inhibits mediator release from
basophils and mast cells. It inhibits enzyme calcineurin phos-
phatase activity, resulting in decreased IL-2 synthesis and
secretion, hence inhibiting T cell multiplication (Letko et al.,
1999).
Topical tacrolimus has been extensively used in dermatol-
ogy for the treatment of atopic dermatitis, plaque psoriasis,
pyoderma gangrenosum, and generalized erythroderma with
good results (Leonardi et al., 2006). With such an insight, this
clinical trial was done to assess the safety and efﬁcacy of 0.1%
tacrolimus powder in Oraguard-B when treating the lesions of
patients with symptomatic OLP.
2. Materials and methods
Approval to conduct the study was given by the Ethics Com-
mittee of the Kothiwal Dental College and Research Centre,Moradabad, India, in compliance with the principles of the
Declaration of Helsinki. The tacrolimus powder for the study
was sponsored by Ranbaxy Pharmaceuticals (Gurgaon, Har-
yana, India) and the base Oraguard-B was purchased from
Colgate Palmolive (New York, NY, USA).
The tacrolimus ointment was made using tacrolimus powder
with Oraguard-B as a base. Five hundred milligrams of tacroli-
mus powder was mixed with 300 g Oraguard-B on a clean glass
slab using a stainless steel mixing spatula under aseptic condi-
tions. This preparation was then packed into plastic containers
so that each container contained at least 20 g of the medication.
The subjects for the study were selected among the patients
attending the outpatient department who fulﬁlled the inclusion
and exclusion criteria. A written consent was obtained from
every patient before initiating treatment. The following inclu-
sion and exclusion criteria were designed for the study.
2.1. Inclusion criteria
(a) Clinical evidence of the lesion.
(b) Histopathological conﬁrmation of the disease.
(c) Patients recalcitrant to treatment with other medications
or having recurrent lesions (see Table 1).2.2. Exclusion criteria
Patients on medication for other systemic diseases.2.3. Study intervention
The study preparation was administered for 3–6 months or till
the lesions had completely healed, then the patients were in-
structed to use the medication three times daily after meals.
Detailed information regarding the study protocol and
tacrolimus therapy was explained verbally to each subject. Sub-
sequently, informed consent was obtained. Aminimum data set
(patient age, gender, medical history, and habits) was docu-
mented by means of case history proforma. All topical and sys-
temic medication previously prescribed for OLP was stopped at
least 2 weeks before the initiation of tacrolimus therapy. Use of
routine analgesics was allowed during the course of the study.
Subjective assessment was done by means of a visual analogue
scale (VAS) for symptoms of pain and burning. The extent of
eroded or ulcerated areas was recorded by using a scoring sys-
tem based on the variation criteria (Table 2). Before the com-
mencement of therapy, baseline subjective and objective
assessments were recorded together with blood pressure, com-
plete blood count, liver biochemistry, blood urea, and random
blood glucose levels. The patients were instructed to sparingly
apply 0.1% tacrolimus powder in Oraguard-B topically over
the affected areas after meals and not to eat or rinse for at least
45 min after applying the study preparation.
Table 1 Past history of treatment.
Serial no. Patient’s age/sex Past history of treatment
1 45/F Tab Betnesol 5 mg thrice daily (swish and swallow), Kenacort topical ointment and Tablet Vermisol
2 45/F No past history of treatment
3 38/F Tab Vermisol, Topical Kenacort ointment
4 55/F No past drug history
5 49/M History of antioxidant intake for 15–20 days
6 30/F No past history of treatment
7 58/M Topical Kenacort ointment, Tab Vermisole, Tab Betnesol, Tab Prednisolone
8 45/F Topical Kenacort and Prednisolone
9 40/F Tab Vermisole, Orasep-OT mouth paint. Betnisol 5 mg, Kenacort topical ointment
10 22/M No past history of treatment
11 30/M Topical Kenacort ointment, Tab Vermisol, Tab Prednisolone
12 27/M Topical Kenacort, Mucopain ointment
13 42/F No past history of treatment
14 55/F Orasep-OT mouth paint
15 40/M No past history of treatment
16 32/F Topical Kenacort, Betnesol (swish and swallow)
17 44/M Tab Vermisol, Tab Prednisolone, and topical Kenacort
18 30/F Topical Kenacort ointment
19 18/F No past history of treatment
20 24/M No past history of treatment
Table 2 Clinical scoring.
Score Clinical status
0 No Lesion
1 White striae only
2 White striae and erosion <1 cm2
3 White striae and erosion >1 cm2
4 White striae and ulceration <1 cm2
5 White striae and ulceration >1 cm2
Adopted from J. Am. Acad. Dermatol. 2002;46:35–41.
Table 3 Demographic and clinical characteristics of the
patients.
Serial
no.
Characteristic Statistic
1 Mean age ± SD (range)
in years
38.25 ± 11.19 (18–58)
2 Male:female 7 (35%):13 (65%)
3 No. of patients with
involvement of right
buccal mucosa (%)
17 (85%)
4 No. of patients with
involvement of left
buccal mucosa (%)
17 (85%)
5 No. of patients with
desquamative gingivitis
(%)
6 (30%)
6 Mean duration of
treatment ± SD (range)
in days
81.8 ± 44.4 (30–183)
Figure 1 (Pre treatment) papular lichen planus involving left
buccal mucosa.
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treatment response.2.4. Data analysis
As the sample size was small, the distributions were checked
for normality using the Kolmogorov–Smirnov test and were
found to be asymmetric and abnormal, hence a nonparametric
analysis plan was adopted. Changes from pretreatment values
for VAS and clinical scoring were compared using the Wilco-
xon signed rank test. The conﬁdence level of the study was
kept at 95%, hence a P value less than 0.05 indicated a statis-
tically signiﬁcant change.
3. Results
Twenty patients (13 women and 7 men) were enrolled in the
study. Their mean age was 38.25 ± 11.19 (range, 18–58), and
the duration of treatment ranged from 30 to 183 days, with a
mean of 81.8 ± 44.4 days. Demographic and clinical character-
istics of the patients are shown in Table 3. None of the patients
146 U. Malik et al.withdrew from the study. All 20 patients enrolled for the study
were responsive to the topical tacrolimus therapy; 11 patients
had complete resolution of the lesions including the reticular
component, while 14 had complete healing of the erosive com-
ponent. Desquamative gingivitis was present in 6 patients, of
which 3 showed complete healing. Clinical improvement in
the various forms of symptomatic lichen planus has been ob-
served in the study (Figs. 1–4). Relief in pain symptoms re-Figure 2 (Post treatment) healed lesions on the left buccal
mucosa.
Figure 3 (Pre treatment) erosive lesions over the right buccal
mucosa.corded by the visual analogue scale showed complete relief of
pain (Graph 1).
No serious adverse effects were reported by any of the pa-
tients under study. The only adverse effect reported with the
use of tacrolimus therapy was a burning sensation on the ﬁrst
3–4 applications, which was not so marked as to discontinue
use. Moreover, the burning sensation diminished spontane-
ously on subsequent applications, and it was present in only
5 patients. No patient developed a candidal infection during
the tacrolimus therapy. Values of the visual analogue scale,
both pre- and posttreatment, for male and female patients in
terms of mean ±, standard deviation, and paired t test to test
the signiﬁcant differences in pre- and postobservational scoresFigure 4 (Post treatment) healed mucosal lesion.
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Graph 1 The above bar graph shows the pre-treatment and post-
treatment visual analogue scale results in males and females on
topical tacrolimus therapy. A signiﬁcant difference is observed on
the bar graph in pre and post treatment results.
Table 4 VAS and Clinical score in pre and post-treatment patients.
Serial no. Parameter Pre-treatment Post-treatment Change in values Signiﬁcance of change
(Wilcoxon signed rank test)
Mean SD Mean SD Mean SD z p
1 VAS score (n= 20) 4.95 2.23 0.50 1.24 4.45 2.11 3.956 <0.001
2 Clinical score (right buccal mucosa) (n= 17) 2.71 0.89 0.59 0.94 2.12 0.99 3.564 <0.001
3 Clinical score (left buccal mucosa) (n= 17) 2.82 0.53 0.41 0.71 2.41 0.94 3.656 <0.001
4 Clinical score (desquamative gingivitis) (n= 7) 2.71 0.49 0.43 0.79 2.29 0.84 2.414 0.016
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mean VAS and clinical scores was observed (P< 0.05). The
results of this pilot study are encouraging; however, in order
to substantiate it further, it can be done in a more detailed
and objective manner to determine the exact beneﬁt of tacrol-
imus compared with conventional therapies and to examine
the inﬂuence of different dosage regimes and formulations.4. Discussion
Topical tacrolimus was found to be safe and effective in all the
20 patients who participated in the study. There was a decrease
in overall representation of the lesion, which included the sur-
face area and visual analogue scores. The demographic charac-
teristics of our patients were similar to those patients previously
reported (Lozada-Nur and Sroussi, 2006). Moreover, in most
of the previously reported studies, the tacrolimus therapy was
administered only for erosive or ulcerative OLP (Olivier
et al., 2002; Sanchez et al., 2004; Rabnal et al., 2007; Donovan
et al., 2005; Rozycki et al., 2002; Morrison et al., 2002).
Few studies have shown the role of tacrolimus therapy in the
treatment of symptomatic reticular OLP (Olivier et al., 2002).
In our study, 61.1% (13 of 20 patients) complete resolution
of erosive, ulcerated, and even the reticular form of OLP was
observed. A marked improvement in the symptoms of burning
and pain occurred in 80% (16 of 20 patients). Eight of our pa-
tients used the study preparation for the ﬁrst time, and the re-
sults were very promising. In 2 of our patients, healing took
place with pigmentation. Ten patients were followed up for a
period of 3 months. Of these, 5 patients had recurrence of their
lesions but the intensity of recurrence (as observed clinically)
was mild, and the patients were symptomless. Adverse effects
associated with the therapy were mild and transient; they were
limited only to a burning sensation. Because of the established
safe systemic blood levels of tacrolimus, the tests to measure the
blood concentration of tacrolimus were not performed. The
reason for fewer adverse effects may be attributed to the fact
that compounds having a mass unit greater than approximately
500 Da scarcely penetrate the epidermis or epithelium of nor-
mal skin mucosa. Inﬂamed mucosa, due to increased perme-
ability, allows penetration of molecules of higher molecular
weight such as tacrolimus 823 Da. Once the inﬂammation
(and permeability) decreases due to the anti-inﬂammatory
activity of topical tacrolimus, the compound will penetrate
the epithelium less when the lesions have improved, thereby
limiting the potential side effects of this particular regime
(Kaliakatsou et al., 2002). The treatment was not discontinued
on any patient for any reason. In our studies, Oraguard-B has
been a promising base, showing good mucoadhesive propertiesthrough patients’ responses. Since the study was nonblinded
and noncomparative, whether topical tacrolimus can be used
as the ﬁrst line of treatment or used in other concentrations
need to be assessed.
5. Conclusion
The encouraging results of our pilot prospective study lead us
to conclude that topical tacrolimus powder 0.1% in Oraguard-
B is a safe and effective treatment of symptomatic OLP. As per
our ﬁnding, topical 0.1% tacrolimus can be used effectively in
patients whose ere lesions are recalcitrant to treatment with
topical or systemic medications, especially corticosteroids.
However, there is a need of more detailed, randomized, dou-
ble-blinded clinical study with 1 or 2 other traditional medica-
tions to substantiate the ﬁndings of this pilot study.Conﬂict of interest
Nil.
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